We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00230659
First Posted: October 3, 2005
Last Update Posted: May 29, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Hammersmith Hospitals NHS Trust
Information provided by (Responsible Party):
Imperial College London
  Purpose

The inherited disease hereditary haemorrhagic telangiectasia (HHT) causes bleeding from dilated fragile vessels, particularly in the nose and gut. However, many HHT patients develop deep venous thromboses and/or pulmonary embolism, necessitating treatments with anticoagulants that further impair control of their haemorrhagic state. Our initial observations using general coagulation tests suggest that the blood of HHT patients is intrinsically hypercoagulable.

We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of one or several of the proteins which affect blood clotting leading to a hypercoagulable state.

We propose to study levels and activity of blood coagulation factors in people with hereditary haemorrhagic telangiectasia and in normal volunteers. This should define the significance and basis for our initial observations, and will have significant implications for the clinical management of HHT patients.


Condition Intervention Phase
Telangiectasia, Hereditary Hemorrhagic Other: Blood sample to be taken. Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Investigation of Coagulation Parameters in Hereditary Haemorrhagic

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Estimated Enrollment: 100
Study Start Date: August 2004
Study Completion Date: July 2008
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
HHT patients
Patients with hereditary haemorrhagic telangiectasia. Blood sample to be taken.
Other: Blood sample to be taken.
Blood sample to be taken.
Controls
People without hereditary haemorrhagic telangiectasia. Blood sample to be taken.
Other: Blood sample to be taken.
Blood sample to be taken.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients with HHT and normal controls

Exclusion Criteria:

  • Previous thrombosis, recent ill health
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230659


Locations
United Kingdom
Imperial College Hammersmith Campus
London, United Kingdom, W12 0NN
Sponsors and Collaborators
Imperial College London
Hammersmith Hospitals NHS Trust
Investigators
Principal Investigator: Claire Shovlin Imperial College London
  More Information

Publications:
Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT00230659     History of Changes
Other Study ID Numbers: IC/CLS6
First Submitted: September 29, 2005
First Posted: October 3, 2005
Last Update Posted: May 29, 2015
Last Verified: September 2005

Additional relevant MeSH terms:
Telangiectasis
Telangiectasia, Hereditary Hemorrhagic
Vascular Diseases
Cardiovascular Diseases
Hemostatic Disorders
Hemorrhagic Disorders
Hematologic Diseases
Vascular Malformations
Cardiovascular Abnormalities
Congenital Abnormalities